Primary Recipient

FRED HUTCHINSON CANCER RESEARCH CENTER

Amount

$749,121.00

Award Date

7/16/2009

Administering Agency

Health and Human Services, Department of / National Institutes of Health

CDFA Number

93.701

CDFA Program Title

Trans-NIH Recovery Act Research Support

Description

The need for new therapies in relapsed or refractory acute myeloid leukemia (AML) is unquestioned. So far, the CD33-targeting immunoconjugate, gemtuzumab ozogamicin (GO), remains the only FDA-approved drug for this group of patients. However, since GO has

Recipients Connected to Award

Recipient	Role	Amount
FRED HUTCHINSON CANCER RESEARCH CENTER	Primary recipient	$540,265.00
LELAND STANFORD JUNIOR UNIVERSITY, THE	Sub-recipient	$208,856.00